Notably, several preclinical studies in xenograft mouse models have demonstrated that CD47 blockade represents an effective strategy for cancer immunotherapy, as it enables phagocytosis and killing of tumour cells by TAMs [208, 209]. The gene discussed is CD47; the disease is neoplasm.